Literature DB >> 9226781

Making economic evaluations respectable.

U E Reinhardt1.   

Abstract

Policy-makers worldwide are on a quest to control national spending for health care and to enhance the value received for whatever is being spent on health care. One should think that the economic evaluation of clinical practice would play a major role in this quest. Alas, so far it has not, in spite of considerable progress in the development of suitable methodology for such evaluations. The central point of this paper is that the sheer conceptual and practical complexities of economic evaluations in this context are not the only and possibly not the major barrier to a more widespread use of this type of analysis. Just as important may be the suspicion among lay persons that such analyses are easily driven by the assumptions the analyst packages into the analysis which, in turn, opens economic evaluation to hidden bias toward favored results. It is proposed in this paper that this particular barrier to the use of economic evaluations in health policy could be overcome if these analyses were more routinely subjected to the rigorous and penetrating audits that are customary in financial accounting. Typically, research papers in economics are audited through peer review only as to the methodology employed. The suggestions here is that a proper, respectable audit ought to penetrate all the way to the data that were used to produce the findings in a study. The paper concludes with some suggestions on how to develop such an audit infrastructure.

Entities:  

Mesh:

Year:  1997        PMID: 9226781     DOI: 10.1016/s0277-9536(96)00396-6

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  7 in total

1.  The revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals.

Authors:  J L Glennie; G W Torrance; J F Baladi; C Berka; E Hubbard; D Menon; N Otten; M Rivière
Journal:  Pharmacoeconomics       Date:  1999-05       Impact factor: 4.981

2.  Pharmacy benefit management: enhancing the applicability of pharmacoeconomics for optimal decision making.

Authors:  C Daniel Mullins; Junling Wang
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

3.  Computer modelling. The need for careful evaluation and public audit.

Authors:  A Maynard; R F Cookson
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

Review 4.  The role of cost-effectiveness analysis in managed-care decisions.

Authors:  H Grabowski
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

5.  Transparency of economic evaluations of health technologies.

Authors:  Joan Rovira
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

6.  Coauthorship and institutional collaborations on cost-effectiveness analyses: a systematic network analysis.

Authors:  Ferrán Catalá-López; Adolfo Alonso-Arroyo; Rafael Aleixandre-Benavent; Manuel Ridao; Máxima Bolaños; Anna García-Altés; Gabriel Sanfélix-Gimeno; Salvador Peiró
Journal:  PLoS One       Date:  2012-05-29       Impact factor: 3.240

Review 7.  Cost transferability problems in economic evaluation as a framework for an European health care and social costs database.

Authors:  Leticia García-Mochón; Joan Rovira Forns; Jaime Espin
Journal:  Cost Eff Resour Alloc       Date:  2021-07-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.